Last reviewed · How we verify
Xeomin®
Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
Xeomin is a botulinum toxin type A that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Cervical dystonia (spasmodic torticollis), Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Xeomin® |
|---|---|
| Also known as | Incobotulinumtoxin A, IncobotulinumtoxinA, incobotulinumtoxinA, botulinum toxin, NT 201 |
| Sponsor | ATGC Co., Ltd. |
| Drug class | Botulinum toxin type A |
| Target | SNARE complex (acetylcholine release machinery at neuromuscular junction) |
| Modality | Biologic |
| Therapeutic area | Neurology / Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Xeomin contains botulinum toxin type A, which cleaves SNARE proteins required for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, leading to localized muscle relaxation. The effect is temporary, typically lasting 3-4 months, after which the neuromuscular junction recovers.
Approved indications
- Cervical dystonia (spasmodic torticollis)
- Blepharospasm
- Hemifacial spasm
- Glabellar lines (aesthetic indication)
- Crow's feet (aesthetic indication)
- Forehead lines (aesthetic indication)
Common side effects
- Headache
- Injection site pain or bruising
- Eyelid ptosis
- Muscle weakness
- Neck pain
Key clinical trials
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia (PHASE3)
- A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A
- Evaluation of Three Types of Injection for the Treatment of Lateral Epicondylalgia (NA)
- Xeomin® and Gait Related Mobility After Stroke (PHASE4)
- Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xeomin® CI brief — competitive landscape report
- Xeomin® updates RSS · CI watch RSS
- ATGC Co., Ltd. portfolio CI